Business Wire

MYT-NETHERLANDS

11.11.2021 12:02:13 CET | Business Wire | Press release

Share
Q1 FY22 Results: Mytheresa Reports Strong GMV Growth of 29.7% in Q1 FY22 and Continued Strong Profitability

MYT Netherlands Parent B.V. (NYSE: MYTE) (“Mytheresa” or the “Company”), the parent company of Mytheresa Group GmbH, today announced financial results for its first quarter of fiscal year 2022 ended September 30, 2021. The luxury multi-brand digital platform delivered another quarter of strong growth with continued strong profitability.

Michael Kliger, Chief Executive Officer of Mytheresa, said, "We are extremely satisfied with our Q1 FY22 results. We see the strong results again as affirmation of our unique and superior value proposition to customers and brand partners at a global level, as well as excellent operational execution. Q1 FY22 saw Mytheresa cement its position as one of the world's leading digital platforms for luxury fashion.”

Kliger continued, "The shift of consumer demand to online in luxury has clearly accelerated in recent months. We strongly believe this trend will continue in the post-pandemic world, probably reverting to the strong market growth rates we had seen before the pandemic. We will continue to deliver a superior customer experience and deepen our partnerships with the most coveted global brands. Given our strong financial momentum, excellent customer developments, and superior execution, we feel extremely confident to continue achieving strong results for full fiscal year 2022.”

FINANCIAL HIGHLIGHTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2021

  • GMV increase of 29.7% year-over-year to €163.9 million, as compared to €126.4 million in the prior year period
  • Net sales increase of 24.9% year-over-year to €157.8 million
  • Strong gross profit margin of 49.0%, as compared to 46.4% in the prior year period
  • Adjusted EBITDA of €14.0 million, as compared to €10.4 million in the prior year period
  • Adjusted operating income of €11.8 million, as compared to €8.4 million in the prior year period
  • Adjusted net income of €8.2 million, as compared to €5.4 million in the prior year period

RECENT BUSINESS HIGHLIGHTS

Strong Global Expansion:

  • Strong GMV growth across all geographies with +29.7% vs. Q1 FY21 and +65.3% vs. Q1 FY20
  • Strongest net sales growth in the United States with +48.7% vs. Q1 FY21 as market presence continues to grow
  • High-impact top customers events in Europe, China and the United States

Continued Brand Partnerships:

  • Exclusive capsule collections and pre-launches in collaboration with Saint Laurent, Gucci, The Row, Christian Louboutin, Tom Ford, Chloé and many more
  • “Money-can’t buy” physical brand experiences together with Givenchy and Tod’s
  • Successful start of Curated Platform Model (CPM) with first major brand partner

High-quality Customer Growth:

  • LTM growth of active customers by 35.2% reaching 705,000
  • Continued strong repurchase rates of new customer cohorts in FY21 vs. FY20
  • Strong growth of number of top customers with 41.0% in Q1 FY22 vs. Q1 FY21
  • Successful roll-out and expansion of new partnership with Vestiaire Collective offering a unique resale service for Mytheresa’s high-end luxury customers

Consistent Strong Operational Performance:

  • Maintained business continuity across all operations with focus on health and well-being of all Mytheresa employees as top priority
  • Introduced animal welfare policy and carbon neutrality as of Q1 FY22
  • Continued to have very high customer satisfaction with a Net Promoter Score of 83.0% in Q1 FY22
  • Achieved strong gross profit margin based on high full-price share of sales

BUSINESS OUTLOOK

For the full fiscal year ending June 30, 2022, we confirm our previous guidance, but increase our expectations regarding net sales:

  • GMV in the range of €750 million to €770 million, representing a 22% to 25% growth
  • Active customer growth of 22% to 25%, enlarging the customer base to 820,000 to 845,000 active customers
  • Net sales at €700 million to €720 million
  • Gross profit at €345 million to €355 million, representing a 21% to 24% growth
  • Adjusted EBITDA margin at the upper half of the long term range of 7% to 9%

The foregoing forward-looking statements reflect Mytheresa’s expectations as of today's date. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. Mytheresa does not intend to update its forward-looking statements until its next quarterly results announcement, other than in publicly available statements.

CONFERENCE CALL AND WEBCAST INFORMATION

Mytheresa will host a conference call to discuss its first quarter of fiscal year 2022 financial results on November 11, 2021 at 8:00am Eastern Time. Those wishing to participate via webcast should access the call through Mytheresa’s Investor Relations website at https://investors.mytheresa.com . Those wishing to participate via the telephone may dial in at +1 (833) 979-2860 (USA) or +1 (236) 714-2917 (International). A replay will be available via webcast through Mytheresa’s Investor Relations website. The telephone replay will be available from 11:00am Eastern Time on November 11, 2021, through November 18, 2021, by dialing +1 (800) 585-8367 (USA) or +1 (416) 621-4642 (International). The replay passcode will be 9083117.

FORWARD LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make.

You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent our management’s beliefs and assumptions only as of the date such statements are made.

Further information on these and other factors that could affect our financial results is included in filings we make with the U.S. Securities and Exchange Commission (“SEC”) from time to time, including the section titled “Risk Factors” included in the form 20-F filed on October 15, 2021 under Rule 424(b)(4) of the Securities Act. These documents are available on the SEC’s website at www.sec.gov and on the SEC Filings section of the Investor Relations section of our website at: https://investors.mytheresa.com .

ABOUT NON-IFRS FINANCIAL MEASURES AND OPERATING METRICS

We review a number of operating and financial metrics, including the following business and non-IFRS metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We present Adjusted EBITDA, Adjusted Operating Income and Adjusted Net Income because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. Further, we believe these measures are helpful in highlighting trends in our operating results, because they exclude the impact of items that are outside the control of management or not reflective of our ongoing operations and performance. Adjusted EBITDA, Adjusted Operating Income, and Adjusted Net Income have limitations, because they exclude certain types of expenses. We use Adjusted EBITDA, Adjusted Operating Income, Adjusted Net Income as supplemental information only. You are encouraged to evaluate each adjustment and the reasons we consider it appropriate for supplemental analysis.

Our non-IFRS financial measures include:

  • Adjusted EBITDA is a non-IFRS financial measure that we calculate as net income before finance expense (net), taxes, and depreciation and amortization, adjusted to exclude U.S. sales tax expenditures temporarily borne by us through the fourth quarter of fiscal year 2020, IPO preparation and transaction costs and share-based compensation expenses.
  • Adjusted Operating Income is a non-IFRS financial measure that we calculate as operating income, adjusted to exclude U.S. sales tax expenditures temporarily borne by us through the fourth quarter of fiscal year 2020, any IPO preparation and transaction costs and share-based compensation expenses.
  • Adjusted Net Income is a non-IFRS financial measure that we calculate as net income, adjusted to exclude U.S. sales tax expenditures temporarily borne by us, finance expenses on our Shareholder Loans, IPO preparation and transaction costs, share-based compensation expenses and related income tax effects.

We are not able to forecast net income (loss) on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting certain items that affect net income (loss), including, but not limited to, Income taxes and Interest expense and, as a result, are unable to provide a reconciliation to forecasted Adjusted EBITDA.

Gross Merchandise Value (GMV) means the total Euro value of orders processed. GMV is inclusive of merchandise value, shipping and duty. It is net of returns, value added taxes and cancellations. We view GMV as an operating metric.

ABOUT MYTHERESA

Mytheresa is one of the leading global luxury fashion e-commerce platforms. Mytheresa was launched in 2006 and offers ready-to-wear, shoes, bags and accessories for women, men and kids. The highly curated edit focuses on true luxury with designer brands such as Bottega Veneta, Burberry, Dolce & Gabbana, Gucci, Loewe, Loro Piana, Moncler, Prada, Saint Laurent, Valentino and many more. Mytheresa's unique digital experience is based on a sharp focus on high-end luxury shoppers, exclusive product and content offerings, leading technology and analytical platforms as well as high quality service operations. The NYSE listed company reported €612.1 million net sales (+36.2% vs. FY20) in its first fiscal year as a public company.

For more information, please visit https://investors.mytheresa.com/ .

MYT Netherlands Parent B.V.

Financial Results and Key Operating Metrics
(Amounts in € millions)

 

Three Months Ended

 

 

 

 

 

 

 

September

30, 2020

 

September

30, 2021

 

Change

in % / BPs

 

 

 

 

 

 

(in millions) (unaudited)

 

 

 

 

 

Gross Merchandise Value (GMV)

€ 126.4

 

€ 163.9

 

29.7%

Active customer (LTM in thousands)

522

 

705

 

35.2%

Total orders shipped (LTM in thousands)

1,168

 

1,580

 

35.3%

 

 

 

 

 

 

Net sales

€ 126.4

€ 157.8

24.9%

Gross profit

€ 58.7

€ 77.3

31.8%

Gross profit margin(1)

46.4%

49.0%

260 BPs

Adjusted EBITDA(2)

€ 10.4

€ 14.0

34.4%

Adjusted EBITDA margin(1)

8.3%

8.9%

60 BPs

Adjusted Operating Income(2)

€ 8.4

€ 11.8

40.7%

Adjusted Operating Income margin(1)

6.7%

7.5%

80 BPs

Adjusted Net Income(2)

€ 5.4

€ 8.2

51.7%

Adjusted Net Income margin(1)

4.3%

5.2%

90 BPs

(1)

As a percentage of net sales.

(2)

EBITDA, adjusted EBITDA, adjusted Operating Income, adjusted net income are measures not defined under IFRS. For further information about how we calculate these measures and limitations of its use, see above.

MYT Netherlands Parent B.V.

Financial Results and Key Operating Metrics
(Amounts in € millions)

The following are reconciliations of Adjusted EBITDA, Adjusted Operating Income, and Adjusted Net Income to their most directly comparable IFRS financial measures:

 

Three Months Ended

 

 

 

 

 

 

 

September

30, 2020

 

September

30, 2021

 

Change

in %

 

 

 

 

 

 

(in millions) (unaudited)

 

 

 

 

 

Net income

€ 9.6

 

€ (7.3)

 

(175.8%)

Finance expenses, net

€ (5.2)

 

€ 0.2

 

(103.7%)

Income tax expense

€ 3.8

 

€ 3.4

 

(9.4%)

Depreciation and amortization

€ 2.0

 

€ 2.2

 

8.0%

thereof depreciation of right-of use assets

€1.3

 

€ 1.3

 

2.9%

EBITDA

€ 10.2

 

€ (1.5)

(114.8%)

IPO preparation and transaction costs(1)

€ 0.2

 

€ 0.0

(100.0%)

IPO-related and preceding share-based compensation(2)

€ 0.0

 

€ 15.5

N/A

Adjusted EBITDA

€ 10.4

 

€ 14.0

34.4%

 

Three Months Ended

 

 

 

 

 

 

 

September

30, 2020

 

September

30, 2021

 

Change

in %

 

 

 

 

 

 

(in millions) (unaudited)

 

 

 

 

 

Operating Income

€ 8.2

€ (3.7)

(145.1%)

IPO preparation and transaction costs(1)

€ 0.2

€ 0.0

(100.0%)

IPO-related and preceding share-based compensation(2)

€ 0.0

€ 15.5

N/A

Adjusted Operating Income

€ 8.4

€ 11.8

40.7%

MYT Netherlands Parent B.V.

Financial Results and Key Operating Metrics
(Amounts in € millions)

 

Three Months Ended

 

 

 

 

 

 

 

September

30, 2020

 

September

30, 2021

 

Change

in %

 

 

 

 

 

 

(in millions) (unaudited)

 

 

 

 

 

Net Income

€ 9.6

 

€ (7.3)

 

(175.8%)

IPO preparation and transaction costs(1)

€ 0.2

 

€ 0.0

 

(100.0%)

IPO-related and preceding share-based compensation (2)

€ 0.0

 

€ 15.5

 

N/A

Finance expenses on shareholder loans (3)

€ (5.5)

 

€ 0.0

 

(100.0%)

Income tax effect(4)

€ 1.1

 

€ 0.0

 

(100.0%)

Adjusted Net Income

€ 5.4

 

€ 8.2

 

51.7%

(1)

Represents non-recurring professional fees, including consulting, legal and accounting fees, related to this offering, which are classified within selling, general and administrative expenses.

(2)

In fiscal 2021, with the effective IPO, certain key management personnel received a one-time granted share-based compensation, these expenses will be recognized upon defined vesting schedules in the future periods. We do not consider these expenses to be indicative of our core operating performance.

(3)

Our Adjusted Net Income excludes finance expenses associated with our Shareholder Loans, which we do not consider to be indicative of our core performance. We did not receive any cash proceeds under the Shareholder Loans, which originated as part of the Neiman Marcus acquisition in 2014. In January 2021, we repaid our Shareholder Loans (principal plus outstanding interest) using a portion of the net proceeds from our initial public offering.

(4)

Reflects adjustments to historical income tax expense to reflect changes in taxable income for each of the periods presented due to changes in finance expenses related to the Shareholder Loans, assuming a statutory tax rate of 27.8%.

MYT Netherlands Parent B.V.

Unaudited Condensed Consolidated Statements of Profit and Comprehensive Income
(Amounts in € thousands, except share and per share data)

 

 

Three Months Ended

 

 

 

(in € thousands)

 

September 30, 2020

 

September 30, 2021

 

 

 

 

 

Net sales

 

126,359

 

157,832

Cost of sales, exclusive of depreciation and amortization

 

(67,678)

 

(80,516)

Gross profit

 

58,681

 

77,316

Shipping and payment cost

 

(14,833)

 

(19,966)

Marketing expenses

 

(17,441)

 

(22,427)

Selling, general and administrative expenses

 

(15,556)

 

(36,158)

Depreciation and amortization

 

(2,021)

 

(2,182)

Other expense (income), net

 

(621)

 

(281)

Operating income

 

8,209

 

(3,699)

Finance income

 

8,291

 

-

Finance costs

 

(3,109)

 

(189)

Finance income (costs), net

 

5,182

 

(189)

Income (loss) before income taxes

 

13,391

 

(3,888)

Income tax (expense) income

 

(3,762)

 

(3,408)

Net income (loss)

 

9,629

 

(7,296)

Cash Flow Hedge

 

871

 

(1,081)

Income Taxes related to Cash Flow Hedge

 

(242)

 

267

Foreign currency translation

 

-

 

(25)

Other comprehensive income (loss)

 

629

 

(839)

Comprehensive income (loss)

 

10,258

 

(8,136)

 

 

 

 

 

Basic and diluted earnings per share

€

0.14

€

(0.09)

Weighted average ordinary shares outstanding (basic and diluted)

 

70,190,687

 

84,525,207

MYT Netherlands Parent B.V.

Unaudited Condensed Consolidated Statements of Financial Position
(Amounts in € thousands)

(in € thousands)

June 30, 2021

September 30, 2021

Assets

Non-current assets

Intangible assets and goodwill

155,611

155,482

Property and equipment

 

8,810

 

8,459

Right-of-use assets

14,009

22,710

Total non-current assets

178,430

186,651

Current assets

 

 

Inventories

 

247,054

 

264,955

Trade and other receivables

5,030

3,755

Other assets

 

14,667

 

15,240

Cash and cash equivalents

76,760

55,685

Total current assets

 

343,510

 

339,635

Total assets

521,941

526,286

 

 

Shareholders’ equity and liabilities

 

 

Subscribed capital

1

1

Capital reserve

 

444,951

 

461,086

Accumulated Deficit

(60,837)

(68,133)

Other comprehensive income

 

1,602

 

763

Total shareholders’ equity

385,718

393,716

 

 

Non-current liabilities

 

 

 

 

Provisions

 

717

 

734

Lease liabilities

8,786

17,397

Deferred tax liabilities

 

2,308

 

3,161

Total non-current liabilities

11,811

21,292

Current liabilities

 

 

 

 

Tax liabilities

14,293

15,750

Lease liabilities

 

5,361

 

5,459

Contract liabilities

10,975

7,773

Trade and other payables

 

43,558

 

27,222

Other liabilities

50,225

55,073

Total current liabilities

 

124,412

 

111,277

Total liabilities

136,223

132,569

Total shareholders’ equity and liabilities

 

521,941

 

526,286

MYT Netherlands Parent B.V.

Unaudited Condensed Consolidated Statements of Changes in Equity
(Amounts in € thousands)

(in € thousands)

 

Subscribed

capital

 

Capital

reserve

 

Accumulated

deficit

 

Hedging

reserve

 

Foreign

currency

translation

reserve

 

Total

shareholders’

equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of July 1, 2020

 

1

 

91,008

 

(28,234)

 

-

 

 

1,602

 

64,377

Net income

 

-

 

-

 

6,350

 

-

 

-

 

6,350

Other comprehensive income

 

-

 

-

 

-

 

629

 

4,730

 

4,730

Comprehensive income

 

-

 

-

 

6,350

 

629

 

4,730

 

11,080

Share-based compensation

 

-

7

-

 

 

-

7

Balance as of September 30, 2020

 

1

 

91,015

 

(18,605)

 

629

 

1,602

 

74,642

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of July 1, 2021

 

1

 

444,951

 

(60,837)

 

-

 

1,602

 

385,718

Net income

 

-

 

-

 

(7,296)

 

-

 

-

 

(7,296)

Other comprehensive income

 

-

 

-

 

-

 

(814)

 

(25)

 

(839)

Comprehensive income

 

-

 

-

 

(7,296)

 

(814)

 

(25)

 

(8,136)

Share-based compensation

 

-

 

16,134

 

-

 

-

 

-

 

16,134

Balance as of September 30, 2021

 

1

 

461,086

 

(68,133)

 

(814)

 

1,577

 

393,716

MYT Netherlands Parent B.V.

Unaudited Condensed Consolidated Statements of Cash Flows
(Amounts in € thousands)

 

Three Months ended September 30,

(in € thousands)

 

2020

 

2021

 

 

 

 

 

Net income (loss)

 

9,629

 

(7,296)

Adjustments for

 

 

 

 

Depreciation and amortization

 

2,021

 

2,182

Finance (income) costs, net

 

(5,182)

 

189

Share-based compensation

 

7

 

16,134

Income tax expense

 

3,762

 

3,408

Change in operating assets and liabilities

 

 

 

 

Increase in provisions

 

129

 

17

Increase in inventories

 

(33,328)

 

(17,901)

(Increase) decrease in trade and other receivables

 

(970)

 

1,274

Decrease (increase) in other assets

 

1,980

 

(519)

(Decrease) increase in other liabilities

 

2,879

 

3,713

Increase (decrease) in contract liabilities

 

600

 

(3,202)

Increase (decrease) in trade and other payables

 

(14,905)

 

(16,336)

Income taxes paid

 

-

 

(831)

Net cash provided by (used in) operating activities

 

(33,378)

 

(19,166)

Expenditure for property and equipment and intangible assets

 

(904)

 

(356)

Net cash (used in) investing activities

 

(904)

 

(356)

Interest paid

 

(547)

 

(189)

Proceeds from bank liabilities

 

37,810

 

-

Repayment of liabilities from banks

 

(5,000)

 

-

Payment of lease liabilities

 

(1,429)

 

(1,339)

Net cash (used in) provided by financing activities

 

30,834

 

(1,528)

Net increase (decrease) in cash and cash equivalents

 

(3,448)

 

(21,050)

Cash and cash equivalents at the beginning of the period

 

9,367

 

76,760

Effects of exchange rate changes on cash and cash equivalents

 

(19)

 

(25)

Cash and cash equivalents at end of the period

 

5,900

 

55,685

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release

Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De

Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release

Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features

Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye